Publications by authors named "A J Link"

Aspartimidylation is a post-translational modification found in multiple families of ribosomally synthesized and post-translationally modified peptides (RiPPs). We recently reported on the imiditides, a new RiPP family in which aspartimidylation is the class-defining modification. Imiditide biosynthetic gene clusters encode a precursor protein and a methyltransferase that methylates a specific Asp residue, converting it to aspartimide.

View Article and Find Full Text PDF

Increasing physical activity (PA) is recognised as an efficacious approach for preventing and treating cardiometabolic diseases. Recently, the composition of microorganisms living within the gut has been proposed as an important appropriate target for treating these diseases. Whether PA is related to faecal microbiota diversity and composition in humans remains to be ascertained.

View Article and Find Full Text PDF

Community-acquired pneumonia (CAP) is a major global health concern as it is a leading cause of morbidity, mortality and economic burden to the health care systems. In Germany, more than 15,000 people die every year from CAP. Climate change is altering weather patterns, and it may influence the probability and severity of CAP.

View Article and Find Full Text PDF
Article Synopsis
  • CMV reactivation is a significant health issue for patients who have undergone stem cell or organ transplants, leading to increased risks of illness and death.
  • Three CMV-specific Fab-antibodies (A6, C1, C7) have been developed to bind to particular MHC molecules, showing effectiveness in targeting and destroying CMV-infected cells, especially when used in combination with natural killer (NK) cells.
  • The TCR-like antibodies also demonstrated the ability to activate neutrophils to kill target cells, offering a promising treatment option for patients experiencing or at risk of CMV reactivation, with a broader potential patient application than previous methods.
View Article and Find Full Text PDF

There is growing interest in the potential exploitation of the gut microbiome as a diagnostic tool in medicine, but evidence supporting its clinical usefulness is scarce. An increasing number of commercial providers offer direct-to-consumer microbiome diagnostic tests without any consensus on their regulation or any proven value in clinical practice, which could result in considerable waste of individual and health-care resources and potential drawbacks in the clinical management of patients. We convened an international multidisciplinary expert panel to standardise best practices of microbiome testing for clinical implementation, including recommendations on general principles and minimum requirements for their provision, indications, pre-testing protocols, method of analyses, reporting of results, and potential clinical value.

View Article and Find Full Text PDF